BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Skyepharma PLC (SKYEF) CEO To Step Down


5/11/2010 8:37:05 AM

LONDON, UK, 5 May 2010 – SkyePharma PLC (LSE: SKP) announces today that its Chief Executive Officer, Dr. Ken Cunningham, has informed the Board that he intends to step down from the Board, and as Chief Executive Officer, in the fourth quarter 2010, to enable him to focus on a portfolio of non-executive appointments.

An executive search for a replacement Chief Executive Officer is being initiated.

Frank Condella, Chairman of SkyePharma, commented: "The Board thanks Ken for his valuable contribution to the progress of SkyePharma since April 2006 and his excellent stewardship of the Group since his appointment as Chief Executive Officer in September 2008. We are pleased that Ken will continue to manage the Group and, in particular, lead the ongoing discussions with the FDA on Flutiform™. In the meantime, we are undertaking a search, both internal and external, for an equally talented and committed replacement. We are aiming to ensure that there will be a suitable hand over period and Ken has confirmed his intention to assist us in this process."

Ken Cunningham joined the Company in April 2006 and was appointed Chief Executive Officer of SkyePharma PLC on 1st September 2008. Aged 57, Ken is a Non-Executive Director of Xention Limited and Chairman designate of Polytherics Limited. Previously, he was Chief Executive Officer of Arakis Limited, Vice-President European Affairs of Alza Corporation and Vice-President Clinical Development of Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert.

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES